论文部分内容阅读
目的研究布地奈德混悬液联合硫酸特布他林雾化吸入对慢性阻塞性肺病急性加重期(AECOPD)的临床疗效。方法对60例AECOPD住院患者随机分为观察组与对照组。观察组30例,在常规治疗的基础上给予布地奈德混悬液2mg和硫酸特布他林雾化液5mg加生理盐水2ml联合雾化吸入治疗,2次/d;对照组30例,在常规治疗的基础上给予给以硫酸特布他林雾化液5mg加生理盐水2ml治疗,2次/d,对两组患者用药7d后的临床症状、血气分析及第一秒用力呼气容积占预计值百分比(FEV1%预计值)变化情况进行比较分析。结果两组治疗前后PaO2、PaCO2、FEV1%预计值比较,差异有统计学意义(P<0.05),两组间各对应指标相比较,差异均有统计学意义(P<0.05)。两组的年龄、性别、发病、病程等构成情况大致相同。结论布地奈德联合硫酸特布他林雾化吸入对AECOPD能迅速缓解病情,畅通呼吸道,改善肺功能,疗效优于单一用药,是治疗AECOPD的有效选择。
Objective To study the clinical efficacy of budesonide suspension combined with terbutaline sulphate inhalation on acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Sixty patients hospitalized with AECOPD were randomly divided into observation group and control group. 30 cases in the observation group were given budesonide suspension 2mg and terbutaline sulphate aerosol 5mg plus saline 2ml combined with atomizing inhalation on the basis of routine treatment twice a day and control group 30 cases On the basis of routine treatment given terbutaline sulphate aerosol 5mg plus saline 2ml treatment, 2 times / d, two groups of patients after 7d of clinical symptoms, blood gas analysis and first second forced expiratory volume Predicted percentage (FEV1% predicted) changes in the situation for comparative analysis. Results The predicted values of PaO2, PaCO2 and FEV1% before and after treatment in both groups were statistically significant (P <0.05). There were significant differences in the corresponding indexes between the two groups (P <0.05). The two groups of age, gender, morbidity, duration and other components are roughly the same. Conclusions Budesonide combined with terbutaline sulphate nebulization can rapidly relieve the disease, unblock the respiratory tract and improve pulmonary function. AECOPD is more effective than single administration and is an effective treatment for AECOPD.